Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 16/20 | 1.00 |
| ▸ | SLC2A4 | P14672 | 3/20 | 1.00 |
| ▸ | SLC2A8 | Q9NY64 | 1/20 | 0.81 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21500123 | 0.90 | SLC2A4 (1.00) | SLC2A1SLC2A4SLC2A8 | |
| SCHEMBL23269336 | 0.85 | SLC2A1 (0.74) | SLC2A1SLC2A4SLC2A8NR1H3 | |
| SCHEMBL20339799 | 0.84 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8 | |
| SCHEMBL21500126 | 0.84 | SLC2A1 (0.72) | SLC2A1SLC2A4SLC2A8USP2TSHR | |
| SCHEMBL20339794 | 0.83 | SLC2A1 (0.71) | SLC2A1SLC2A4SLC2A8TSHR | |
| SCHEMBL20339753 | 0.82 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8 | |
| SCHEMBL20339353 | 0.81 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8 | |
| SCHEMBL20339757 | 0.81 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8 | |
| SCHEMBL20339275 | 0.81 | SLC2A1 (0.67) | SLC2A1SLC2A4SLC2A8USP2TSHR | |
| SCHEMBL20339979 | 0.79 | SLC2A1 (1.00) | SLC2A1SLC2A4SLC2A8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190321345-A1 | GLUT4 Selective Inhibitors for Cancer Therapy | UNIV EMORY (US) | 2019-10-24 | — | — | US | claimed |
| WO-2018125968-A1 | GLUT4 SELECTIVE INHIBITORS FOR CANCER THERAPY | EMORY UNIVERSITY (US) | 2018-07-05 | — | — | WO | claimed |
| US-20190321345-A1 | GLUT4 Selective Inhibitors for Cancer Therapy | UNIV EMORY (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190321345-A1 | GLUT4 Selective Inhibitors for Cancer Therapy | UNIV EMORY (US) | 2019-10-24 | — | — | US | disclosed |
| US-20190321345-A1 | GLUT4 Selective Inhibitors for Cancer Therapy | UNIV EMORY (US) | 2019-10-24 | — | — | US | disclosed |
| WO-2018125968-A1 | GLUT4 SELECTIVE INHIBITORS FOR CANCER THERAPY | EMORY UNIVERSITY (US) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018125968-A1 | GLUT4 SELECTIVE INHIBITORS FOR CANCER THERAPY | EMORY UNIVERSITY (US) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321345-A1 | GLUT4 Selective Inhibitors for Cancer Therapy | SLC2A4, SLC2A1, SLC2A2 | SLC2A1 2/4885SLC2A4 1/4885SLC2A8 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.